SPONSOR
Shandong Cancer Hospital and Institute
Total Trials
7
Recruiting
7
Phases
Phase 2, Phase 3
Conditions studied: Rhabdomyosarcoma, Recurrent, RefractoryRectal CancerLimited Stage Small Cell Lung CancerHead & Neck Squamous Cell CarcinomaHead & Neck CancerBreast CancerHER2/CEP17 RatioRectal Malignant NeoplasmsThe First Affiliated Hospital of Nanchang University
Shandong Cancer Hospital and Institute is a clinical research sponsor with 7 registered studies on ClinicalTrials.gov, of which 7 are actively recruiting participants. Research covers conditions including Rhabdomyosarcoma, Recurrent, Refractory, Rectal Cancer, Limited Stage Small Cell Lung Cancer, Head & Neck Squamous Cell Carcinoma.
The trial portfolio spans Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Shandong Cancer Hospital and Institute
How many clinical trials has Shandong Cancer Hospital and Institute sponsored?
ClinicalMetric currently tracks 7 clinical trials sponsored by Shandong Cancer Hospital and Institute, of which 7 are actively recruiting participants. These trials cover conditions including Rhabdomyosarcoma, Recurrent, Refractory, Rectal Cancer, Limited Stage Small Cell Lung Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Shandong Cancer Hospital and Institute research focus on?
Shandong Cancer Hospital and Institute clinical trials span Rhabdomyosarcoma, Recurrent, Refractory, Rectal Cancer, Limited Stage Small Cell Lung Cancer, Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer, and additional conditions. The research pipeline includes Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Shandong Cancer Hospital and Institute clinical trial?
To participate in a Shandong Cancer Hospital and Institute trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Shandong Cancer Hospital and Institute trials with current recruitment status updated daily.
Clinical Trials by Shandong Cancer Hospital and Institute
NCT06816771 Phase 2
Recruiting
Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents
Rhabdomyosarcoma, Recurrent, Refractory
NCT07595107
Recruiting
Concordance Between Large Language Model and Multidisciplinary Team Recommendations in Rectal Cancer
Rectal Cancer
NCT04829708 Phase 3
Recruiting
Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy
Limited Stage Small Cell Lung Cancer
NCT07333274 Phase 3
Recruiting
Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
Head & Neck Squamous Cell Carcinoma
NCT07376174
Recruiting
The Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted Therapy
Breast Cancer
NCT07026422 Phase 2
Recruiting
Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT)
Rectal Malignant Neoplasms
NCT05933967 Phase 2
Recruiting
A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma
The First Affiliated Hospital of Nanchang University
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology